CAMBRIDGE, Mass., September 22, 2021 – KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today announced that Qasim Rizvi, Chief Executive Officer of KSQ, will present at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 4:40 PM (ET). The conference is being held September 27-30, 2021.
About KSQ Therapeutics
KSQ Therapeutics is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer and autoimmune disease across multiple drug modalities, including targeted therapies, adoptive cell therapies, and immunotherapies. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. For more information, please visit the company’s website at www.ksqtx.com and follow @ksq_tx on Twitter.
Media Contact:
Cory Tromblee
cory@scientpr.com
© 2024 KSQ Therapeutics, Inc. All rights reserved.